For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Context Therapeutics Inc (NASDAQ: CNTX) closed at $0.79 in the last session, down -5.95% from day before closing price of $0.84. In other words, the price has decreased by -$5.95 from its previous closing price. On the day, 0.52 million shares were traded.
Ratios:
We take a closer look at CNTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 36.91 and its Current Ratio is at 36.91. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on January 08, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $4.
On November 25, 2024, D. Boral Capital started tracking the stock assigning a Buy rating and target price of $9.
On May 16, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $4.50.Piper Sandler initiated its Overweight rating on May 16, 2024, with a $4.50 target price.
Stock Price History:
Over the past 52 weeks, CNTX has reached a high of $2.75, while it has fallen to a 52-week low of $0.77. The 50-Day Moving Average of the stock is -24.74%, while the 200-Day Moving Average is calculated to be -56.01%.
Shares Statistics:
A total of 75.00M shares are outstanding, with a floating share count of 43.75M. Insiders hold about 41.67% of the company’s shares, while institutions hold 56.83% stake in the company.
Earnings Estimates
The current rating of Context Therapeutics Inc (CNTX) is the result of assessments by 5.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.06 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.49 and -$0.79 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.41, with 6.0 analysts recommending between -$0.24 and -$0.87.
